Versican Plus L4
Active substance
ATC code
Species
Dogs.
Indications
Active immunisation of dogs from 6 weeks of age:
− | to prevent clinical signs, infection and urinary excretion caused by L. interrogans serogroup Australis serovar Bratislava, |
− | to prevent clinical signs and urinary excretion and reduce infection caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae and |
− | to prevent clinical signs and reduce infection and urinary excretion caused by L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa. |
Onset of immunity:
4 weeks after completion of the primary course.
Duration of immunity:
At least one year following the primary vaccination course for all components of Versican Plus L4.
Dose to be administered and administration route
Subcutaneous use.
Dosage and route of administration:
Shake well and administer immediately the entire contents (1 ml) of the product.
Primary vaccination scheme:
Two doses of Versican Plus L4 3-4 weeks apart from 6 weeks of age.
Re-vaccination scheme:
A single dose of Versican Plus L4 to be given annually.
Adverse reactions
Dogs:
Common (1 to 10 animals / 100 animals treated): | injection site swelling1 |
Rare (1 to 10 animals / 10,000 animals treated): | hypersensitivity reaction2 (anaphylaxis, angioedema, circulatory shock, collapse, diarrhoea, dyspnoea, vomiting) anorexia, decreased activity |
Very rare (<1 animal / 10,000 animals treated, including isolated reports): | hyperthermia, lethargy, malaise immune mediated haemolytic anaemia, immune mediated haemolytic thrombocytopenia, immune mediated polyarthritis |
1 A transient swelling (up to 5 cm) which can be painful, warm or reddened. Any such swelling will either have spontaneously resolved or be greatly diminished by 14 days after vaccination.
2 If a hypersensitivity reaction occurs, appropriate treatment should be administered without delay. Such reactions may evolve to a more severe condition which may be life-threatening.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See section “Contact details” of the package leaflet.
